Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $8.6052W HIGH $17.79
Volume
18.18 K
Value Traded
7.37 M
Short % Float
8.25%
+0.46%Week
-12.95%1 Month
-13.23%3 Month
+2.41%6 Month
-4.41%5 Year
-4.41%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
494.45 M
EPS (TTM)
-1.53
P/E Ratio
-
Ent. Value
259.30 M
Total Shares
37.62 M
Float Shares
29.62 M
Insiders
21.27%
Institutions
72.94%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
CTNM Catalyst Timeline
Dated clinical, regulatory and corporate events for Contineum Therapeutics, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Contineum Therapeutics, Inc.
22Total events
5Upcoming
4Tier-1 (high impact)
2026 to 2029Coverage
Upcoming catalysts 2
Event history 16
▼Primary Endpoint MissedJNJ-5120Clinical Data
MOONLIGHT-1 Phase 2 trial did not meet primary efficacy endpoint (MADRS change at Day 5 vs placebo)
Major Depressive Disordersource ↗
▲Safety Data UpdateJNJ-5120Clinical Data
JNJ-5120/PIPE-307 well-tolerated with no new safety signals in MOONLIGHT-1
Major Depressive Disordersource ↗
▼Restructuring LayoffsCorporate
Contineum streamlined discovery programs resulting in limited workforce reduction including CSO departure
▼Management ChangeCorporate
Contineum Chief Scientific Officer Daniel Lorrain, Ph.D. departed as part of research team reduction
●PublicationPIPE-791Presentation
Publication of discovery of PIPE-791 in Journal of Medicinal Chemistry
idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF)source ↗
◆Enrollment CompletePIPE-307Trial
Estimated completion of Moonlight-1 trial of PIPE-307/JNJ-89495120
major depressive disordersource ↗
◆Trial CompletionPIPE-307Trial
Estimated completion of Moonlight-1 trial
major depressive disordersource ↗
◆Enrollment CompletePIPE-307Trial
Estimated completion of Moonlight-1 trial
major depressive disordersource ↗
▲Enrollment CompleteJNJ-5120Trial
Johnson & Johnson completed enrollment of 107 participants in Phase 2 MOONLIGHT-1 trial of JNJ-5120/PIPE-307 in MDD
major depressive disordersource ↗
▲Topline ReadoutPIPE-791Clinical Data
Contineum reported positive topline data from exploratory Phase 1b trial of PIPE-791 in chronic pain
chronic osteoarthritis pain or chronic low back painsource ↗
▲Primary Endpoint MetPIPE-791Clinical Data
Phase 1b trial of PIPE-791 met primary objective of assessing safety and tolerability
chronic osteoarthritis pain or chronic low back painsource ↗
▲First Patient DosedPIPE-791Trial
Contineum initiated patient dosing in PROPEL-IPF Phase 2 trial of PIPE-791 in IPF
idiopathic pulmonary fibrosissource ↗
Past FDA Catalysts and PDUFA Decisions
How CTNM actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-06-30 | PIPE-791 | Phase 1b topline data readout | Phase 1b |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
C42 / 100
Pipeline Score
$582M
Pipeline Value
Fair Value
Valuation Signal
3
Drugs Scored
1.2x
rNPV / MCap
Top 33%
Micro Cap(rank 218 of 658)
Percentile Rank
Contineum Therapeutics, Inc. carries a moderate pipeline score (42/100), with $1.5B risk-adjusted pipeline value, led by PIPE-307 in Relapsing Remitting Multiple Sclerosis (Phase 2), across $89B in total addressable markets.
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| PIPE-307 Small moleculeCompletedNCT06083753 | Relapsing Remitting Multiple Sclerosis | Phase 2 | COMPLETED | 182 | Aug 4, 2025 |
Clinical Trial Results
Readouts, endpoints and source filings for every CTNM program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| JNJ-5120/PIPE-307 | Major Depressive Disorder | Phase 2 | 2026-09-14 | no significant difference from placebo at Day 5Read More | Contineum Therapeutics Reports Phase 2 Results for JNJ-5120/PIPE-307 for the Treatment of Major Depressive DisorderRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Stengone Carmine N.Director, Officer (CEO and President) | Option | 2,500 19,717 held | $1.01 | 09/08/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in CTNM
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| PERCEPTIVE ADVISORS LLC | 0.3 % | 20.58 M | 1.26 M |
CTNM Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How CTNM ranks across every disease it competes in
Competitive Position is a premium feature
See how CTNM ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialCTNM News
CTNM▼ -6.7%on this news
Contineum Therapeutics Reports Phase 2 Results for JNJ-5120/PIPE-307 for the Treatment of Major Depressive Disorder
Contineum Therapeutics announced that its MOONLIGHT-1 trial for JNJ-5120/PIPE-307 did not meet its primary efficacy endpoint. The trial aimed to assess improvements in depression symptoms using the MADRS scale. Results indicated no significant difference from placebo at Day 5, raising concerns about the treatment's effectiveness for major depressive disorder.
Read more →CTNMContineum Therapeutics to Present at the 2026 Morgan Stanley Global Healthcare Conference
Contineum Therapeutics, a clinical-stage biopharmaceutical company, will present at the 2026 Morgan Stanley Global Healthcare Conference. The presentation is scheduled for September 15th at 5:35 p.m. ET. This event underscores the company's focus on developing therapies for inflammatory and fibrotic diseases.
Read more →CTNMContineum Therapeutics Reports Second-Quarter 2026 Financial Results; Affirms Key Clinical Development Milestones
Contineum Therapeutics has announced its financial results for the second quarter of 2026, highlighting progress in its clinical development initiatives. The company continues to focus on its global Phase 2 trial, PROPEL-IPF, which evaluates PIPE-791 for treating patients with inflammatory and fibrotic diseases. This reflects the company's commitment to addressing significant unmet medical needs.
Read more →CTNM▼ -7%on this news
Contineum Therapeutics Publishes Discovery of Potential Best-in-Class LPAR1 Antagonist PIPE-791 in Journal of Medicinal Chemistry
Contineum Therapeutics has published a discovery regarding its potential best-in-class LPAR1 antagonist, PIPE-791, in the Journal of Medicinal Chemistry. This publication highlights the company's ongoing research and development efforts in the biopharmaceutical sector. Further details about the implications of this discovery are not provided.
Read more →CTNMContineum Therapeutics to Present at the 2026 Goldman Sachs Global Healthcare Conference
Contineum Therapeutics is scheduled to present at the 2026 Goldman Sachs Global Healthcare Conference. Details regarding the presentation content or specific topics have not been disclosed in the article. The event is expected to attract significant attention from industry stakeholders.
Read more →CTNM▼ -6.3%on this news
Contineum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Contineum Therapeutics announced the grant of a non-qualified stock option to a new non-executive employee as part of its 2026 Employment Inducement Equity Incentive Plan. The award includes 51,000 shares of Class A common stock, vesting over four years. This move aligns with Nasdaq Listing Rule 5635(c)(4) and reflects the company's commitment to attracting talent.
Read more →CTNMContineum Therapeutics to Present at the 2026 RBC Capital Markets Global Healthcare Conference
Contineum Therapeutics is scheduled to present at the 2026 RBC Capital Markets Global Healthcare Conference. The details regarding the presentation's content and significance have not been disclosed in the available information.
Read more →CTNM▼ -6.1%on this newsshared move
Contineum Therapeutics Announces Two Upcoming Posters at the American Thoracic Society (ATS) 2026 International Conference
Contineum Therapeutics has announced that it will present two posters at the upcoming American Thoracic Society (ATS) 2026 International Conference. The details regarding the content of the posters and their significance have not been disclosed. This event is anticipated to provide a platform for sharing research findings in the field of thoracic medicine.
Read more →CTNMCONTINEUM THERAPEUTICS REPORTS FIRST-QUARTER 2026 FINANCIAL RESULTS AFFIRMS KEY CLINICAL DEVELOPMENT MILESTONES
Contineum Therapeutics reported its first-quarter 2026 financial results, highlighting positive developments in its clinical trials. The company announced successful topline data from its chronic pain trial and initiated the PROPEL-IPF trial for idiopathic pulmonary fibrosis. With a cash runway extending into 2029, Contineum is focused on advancing its lead clinical indication while managing expenses. However, it still faced a net loss, despite improving from the previous year, and increased general and administrative costs.
Read more →CTNMContineum Therapeutics Reports First-Quarter 2026 Financial Results; Affirms Key Clinical Development Milestones
Contineum Therapeutics has released its financial results for the first quarter of 2026. The company also reaffirmed its commitment to key clinical development milestones. Further details regarding the financial performance and specific milestones were not provided in the article.
Read more →CTNM▲ +7.2%on this newsshared move
Contineum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - May 1, 2026
Contineum Therapeutics has granted inducement awards to two new employees as part of its 2026 Employment Inducement Equity Incentive Plan. Each award includes stock options for 51,000 shares, vesting over four years. This move aligns with Nasdaq Listing Rule 5635(c)(4) and reflects the company's strategy to enhance its workforce as it advances its clinical programs.
Read more →CTNM▲ +6.5%on this news· ran to +20% by day 3shared move
Contineum Therapeutics Reports Positive Topline Data From Its Exploratory PIPE-791 Phase 1b Trial in Chronic Pain
Contineum Therapeutics announced positive topline results from its Phase 1b trial of PIPE-791, a selective LPA1 receptor antagonist for chronic pain. The trial demonstrated that PIPE-791 was well tolerated and showed improvements in pain intensity compared to placebo. The findings support further clinical development of PIPE-791, particularly for chronic osteoarthritis pain and chronic low back pain.
Read more →CTNM▼ -7.1%on this news
CONTINEUM THERAPEUTICS REPORTS FOURTH-QUARTER 2025 FINANCIAL RESULTS AFFIRMS KEY CLINICAL DEVELOPMENT MILESTONES
Contineum Therapeutics has announced its financial results for the fourth quarter of 2025, highlighting the initiation of patient dosing in the PROPEL-IPF Phase 2 trial for PIPE-791, aimed at treating idiopathic pulmonary fibrosis (IPF). The company expects topline data from another trial for PIPE-791 in chronic pain by the second quarter of 2026. Despite a supportive cash position anticipated to last through mid-2029, the company also reported an increased net loss and rising administrative expenses compared to the previous year. CEO Carmine Stengone expressed enthusiasm about the potential of their pipeline program, emphasizing the unmet needs in IPF treatment.
Read more →CTNM▲ +5.4%on this newsshared move
Contineum Therapeutics to Present at the 2026 Leerink Partners Global Healthcare Conference
Contineum Therapeutics, a clinical-stage biopharmaceutical company, will present at the 2026 Leerink Partners Global Healthcare Conference on March 11th. The presentation will highlight their innovative therapies for neuroscience, inflammation, and immunology. The company is advancing several drug candidates in clinical trials, including PIPE-791 and PIPE-307.
Read more →CTNMContineum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - January 28, 2026
Contineum Therapeutics has granted a non-qualified stock option award to a new non-executive employee as part of its 2026 Employment Inducement Equity Incentive Plan. The award consists of 23,000 shares of Class A common stock, with a vesting schedule over four years. This move aligns with Nasdaq Listing Rule 5635(c)(4) and underscores the company's ongoing growth strategy.
Read more →CTNM▼ -5.3%on this news
VP, Head of Biometrics
Contineum Therapeutics is seeking a VP, Head of Biometrics to lead its Biostatistics and Data Management departments. The role involves strategic oversight of biostatistics activities, collaboration with clinical development teams, and ensuring compliance with regulatory standards. Candidates should have extensive experience in the pharmaceutical industry and a strong statistical background.
Read more →CTNMContineum Therapeutics Announces Pricing of Initial Public Offering
Contineum Therapeutics, a clinical stage biopharmaceutical company, has announced the pricing of its initial public offering (IPO) set at $16.00 per share for 6,875,000 shares. The IPO is expected to yield gross proceeds of approximately $110 million and is anticipated to begin trading on The Nasdaq Global Select Market under the ticker CTNM on April 5, 2024. The proceeds will support Contineum's focus on developing therapies for significant clinical impairments in neuroscience, inflammation, and immunology. However, the offering is subject to customary closing conditions, highlighting some uncertainty surrounding its completion.
Read more →About Contineum Therapeutics, Inc.
Headquarters3565 GENERAL ATOMICS COURT, SUITE 200, SAN DIEGO, CA, 92121
BIOPHARMAWATCH ELITE PLUS
Trade the next CTNM catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime